latest update:
[TrialBase DB]

trial summary · NCT07191145

Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)

EarLy Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT): a Parallel Group, Randomized, Double Blind, Placebo Controlled Trial

Trial record from the TrialBase DB dataset, status RECRUITING, condition Post Traumatic Headache, sponsored by Sunnybrook Health Sciences Centre. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07191145phase PHASE3enrollment 80start 2026-11

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Most individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting \> 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.

Source record: https://clinicaltrials.gov/study/NCT07191145

Facts

registry idNCT07191145
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE3
study typeINTERVENTIONAL
lead conditionPost Traumatic Headache
sponsorSunnybrook Health Sciences Centre
sponsor classOTHER
enrollment80
start date2026-11
primary completion2027-06-30
completion2027-12-30
results postednot reported

Conditions

  • Post Traumatic Headache

Interventions

  • Eptinezumab
  • Placebo

Countries

  • Canada

Intervention types: DRUG, OTHER

Work with this record